Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Astrazeneca Pharma I
Join Channel
Consolidated Standalone

Astrazeneca Pharma I

₹5240.5 108.3 | 2.1%

Market Cap ₹13101 Cr.

Stock P/E 94.1

P/B 19.5

Current Price ₹5240.5

Book Value ₹ 268.3

Face Value 2

52W High ₹7208

Dividend Yield 0.31%

52W Low ₹ 3131.1

Edit Ratio

Astrazeneca Pharma I Research see more...

Overview Inc. Year: 1979Industry: Pharmaceuticals & Drugs

AstraZeneca Pharma India Ltd is a biopharmaceutical corporation. The Company makes a speciality of the invention, development and commercialization of prescription medicines, broadly speaking for the remedy of illnesses in 3 therapy regions, along with oncology, cardiovascular, renal and metabolism, and breathing. It additionally offers clinical trial services. Its cardiovascular disease and diabetic medicine brands consist of Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL and Xigduo XR. Its respiratory medicinal drug manufacturers encompass Symbicort and FASENRA. Its oncology medication brands consist of LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex and Arimidex. It offers offerings, along with self-management, diabetes food regimen and nutrients plans, and free telephonic counseling to patients. It operates in over one hundred international locations.

Read More..

Astrazeneca Pharma I Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Astrazeneca Pharma I Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 198 201 232 232 236 250 285 295 311 306
Other Income 3 5 4 4 7 7 8 8 8 10
Total Income 201 206 236 236 243 257 293 304 319 315
Total Expenditure 180 186 194 204 195 213 225 228 258 291
Operating Profit 21 20 42 32 48 44 68 75 61 25
Interest 0 0 0 0 0 0 0 0 1 1
Depreciation 4 4 4 5 3 4 4 4 4 4
Exceptional Income / Expenses 0 0 0 0 0 0 -40 0 16 0
Profit Before Tax 16 16 37 27 44 39 23 71 73 20
Provision for Tax 4 5 9 7 12 10 6 18 21 5
Profit After Tax 12 11 28 20 33 29 17 54 52 16
Adjustments 0 -0 -0 -0 -0 -0 0 0 0 0
Profit After Adjustments 12 11 28 20 33 29 17 54 52 16
Adjusted Earnings Per Share 4.8 4.6 11.2 8.1 13 11.7 6.9 21.5 20.9 6.3

Astrazeneca Pharma I Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 390 474 517 564 544 571 728 832 814 806 1003 1197
Other Income 11 10 8 7 14 12 16 13 13 15 26 34
Total Income 402 484 525 571 558 583 745 845 826 820 1029 1231
Total Expenditure 460 487 531 547 507 525 657 711 678 719 838 1002
Operating Profit -58 -4 -6 23 51 59 88 134 148 101 191 229
Interest 0 0 0 0 0 0 0 1 1 1 1 2
Depreciation 12 10 15 17 16 15 15 19 20 17 16 16
Exceptional Income / Expenses 0 14 0 0 0 0 0 0 0 0 -40 -24
Profit Before Tax -70 0 -21 6 36 44 73 114 127 83 134 187
Provision for Tax 19 1 0 1 15 18 18 42 34 21 35 50
Profit After Tax -90 -1 -21 5 20 26 54 72 93 62 99 139
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -90 -1 -21 5 20 26 54 72 93 62 99 139
Adjusted Earnings Per Share -35.8 -0.2 -8.3 2.1 8 10.4 21.8 28.9 37.3 24.6 39.7 55.6

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 24% 6% 12% 10%
Operating Profit CAGR 89% 13% 26% 0%
PAT CAGR 60% 11% 31% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 61% 11% 19% 17%
ROE Average 18% 18% 19% 4%
ROCE Average 24% 24% 27% 10%

Astrazeneca Pharma I Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 100 172 151 156 223 247 301 364 456 511 589
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 1 39 89 110 23 44 45 74 69
Total Current Liabilities 206 244 260 234 202 219 268 367 373 392 484
Total Liabilities 306 416 412 429 514 575 591 776 874 977 1142
Fixed Assets 25 94 101 97 87 75 75 72 81 74 69
Other Non-Current Assets 117 47 47 65 164 167 103 122 105 138 137
Total Current Assets 165 275 263 267 263 333 413 582 689 765 936
Total Assets 306 416 412 429 514 575 591 776 874 977 1142

Astrazeneca Pharma I Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 49 17 88 23 76 115 114 173 84 352 448
Cash Flow from Operating Activities -6 -1 -46 57 38 9 55 87 105 101 58
Cash Flow from Investing Activities -16 -15 -19 -4 0 -9 4 -171 173 5 18
Cash Flow from Financing Activities -10 86 0 -1 0 0 0 -6 -9 -9 -24
Net Cash Inflow / Outflow -32 71 -64 53 38 -1 59 -90 269 96 52
Closing Cash & Cash Equivalent 17 88 23 76 115 114 173 84 352 448 500

Astrazeneca Pharma I Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) -35.81 -0.2 -8.34 2.1 8.02 10.36 21.78 28.88 37.32 24.64 39.72
CEPS(Rs) -30.9 3.85 -2.22 9.07 14.35 16.26 27.75 36.32 45.37 31.42 46.22
DPS(Rs) 0 0 0 0 0 0 0 1 2 10 16
Book NAV/Share(Rs) 39.9 68.64 60.3 62.41 88.49 97.94 119.48 145.14 181.83 203.78 234.45
Core EBITDA Margin(%) -17.42 -2.75 -2.59 2.88 6.73 8.09 9.74 14.45 16.58 10.65 16.39
EBIT Margin(%) -17.64 0 -3.97 1.01 6.47 7.66 9.93 13.78 15.69 10.38 13.37
Pre Tax Margin(%) -17.64 0 -3.97 1.01 6.47 7.66 9.93 13.64 15.56 10.26 13.31
PAT Margin (%) -22.47 -0.11 -3.97 0.92 3.65 4.53 7.44 8.65 11.42 7.61 9.85
Cash Profit Margin (%) -19.39 1.99 -1.06 3.98 6.54 7.11 9.48 10.87 13.88 9.7 11.47
ROA(%) -28.28 -0.14 -5.04 1.25 4.25 4.76 9.34 10.57 11.31 6.65 9.37
ROE(%) -61.95 -0.38 -12.93 3.43 10.63 11.12 20.03 21.83 22.83 12.78 18.13
ROCE(%) -48.62 0 -12.93 3.76 18.74 18.65 26.53 34.61 31.24 17.36 24.49
Receivable days 27.61 30.5 33.27 40.32 41.96 31.15 33.52 35.61 37.62 38.57 35.03
Inventory Days 73.5 68.29 63.23 52.15 44.72 54.51 57.68 61.89 72.59 67.64 59.85
Payable days 138.97 236.01 207.79 192.9 194.34 220.03 237.77 229.92 246.52 220.48 214.92
PER(x) 0 0 0 549.84 117.29 89.4 91.75 82.8 80.66 103.71 81.76
Price/Book(x) 16.39 16.08 15.22 18.53 10.63 9.46 16.72 16.48 16.55 12.54 13.85
Dividend Yield(%) 0 0 0 0 0 0 0 0.04 0.07 0.39 0.49
EV/Net Sales(x) 4.14 5.63 4.39 4.99 4.11 3.84 6.62 6.88 8.82 7.37 7.6
EV/Core EBITDA(x) -27.87 -709.52 -408.16 121.38 43.56 37.42 55.06 42.83 48.37 58.85 39.84
Net Sales Growth(%) -26.45 21.4 9.09 9.02 -3.55 5.02 27.55 14.21 -2.19 -0.98 24.5
EBIT Growth(%) -340.2 100 0 127.66 515.93 23.38 65.91 58.4 11.35 -34.47 60.41
PAT Growth(%) -552.98 99.43 -3994.91 125.24 281.25 29.23 110.15 32.62 29.21 -33.98 61.19
EPS Growth(%) -552.98 99.43 -3994.25 125.24 281.25 29.23 110.15 32.62 29.21 -33.98 61.19
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0 0
Current Ratio(x) 0.8 1.13 1.01 1.14 1.3 1.52 1.54 1.59 1.84 1.95 1.93
Quick Ratio(x) 0.39 0.73 0.68 0.81 1.02 1 1.1 1.14 1.42 1.59 1.54
Interest Cover(x) 0 0 0 0 0 0 0 100.97 117.6 88.41 213.86
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Astrazeneca Pharma I Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 75 75 75 75 75 75 75 75 75 75
FII 2.38 2.38 2.48 2.49 2.61 2.7 2.68 2.69 2.65 2.74
DII 1.14 1.19 1.3 1.32 1.42 1.41 1.91 2.42 2.77 3.77
Public 21.48 21.43 21.22 21.19 20.97 20.89 20.41 19.9 19.58 18.5
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 30% CAGR over last 5 years
  • Debtor days have improved from 220.48 to 214.92days.
  • Company is almost debt free.

Cons

  • Stock is trading at 19.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Astrazeneca Pharma I News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!